Genky DrugStores Co., Ltd.

Genky DrugStores Co., Ltd.

TTSE:9267
3,855.00
JPY
-55.00
(-1.41%)
252.40EPS
13.60P/E
105.12BMarket Cap
Feb 02Next Earn

Total Valuation

JPY

As of September 30, 2026, Genky DrugStores Co., Ltd. carries a market capitalization of 105.12B, placing it among publicly traded companies globally. Its enterprise value stands at 131.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap105.12B
Enterprise Value131.66B

Important Dates

Genky DrugStores Co., Ltd.'s next confirmed earnings release is scheduled for February 2, 2027.

Earnings Date2/2/2027

Share Statistics

As of September 30, 2026, Genky DrugStores Co., Ltd. has 30.51M shares outstanding.

Shares Outstanding30.51M

Valuation Ratios

As of September 30, 2026, Genky DrugStores Co., Ltd. trades at a trailing price-to-earnings ratio of 13.60. The price-to-sales ratio is 0.47, and the price-to-book ratio stands at 1.67.

PE Ratio13.60
PS Ratio0.47
PB Ratio1.67
P/TBV Ratio1.67

Enterprise Valuation

As of September 30, 2026, Genky DrugStores Co., Ltd. trades at an EV/EBITDA multiple of 12.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.16 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 131.66B versus a market cap of 105.12B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.59
EV / EBITDA12.16
EV / EBIT12.16

Financial Position

As of September 30, 2026, Genky DrugStores Co., Ltd. maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 64.18, indicating elevated leverage, while an interest coverage ratio of 29.19 demonstrates strong ability to service its debt obligations.

Current Ratio0.95
Quick Ratio0.26
Debt / Equity64.18
Debt / EBITDA3.74
Interest Coverage29.19

Financial Efficiency

JPY

Over the twelve months ended September 30, 2026, Genky DrugStores Co., Ltd. posted a return on equity (ROE) of 13.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.80 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.23, useful for judging operating efficiency across full business cycles. The company generates approximately 117.51M in revenue per employee across its workforce of 1,907.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.54 indicates how many times Genky DrugStores Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)13.04
Return on Assets (ROA)5.35
Return on Invested Capital (ROIC)7.80
Return on Capital Employed (ROCE)8.23
Revenue Per Employee117.51M
Employee Count1,907.00
Inventory Turnover6.54

Taxes

JPY

Over the twelve months ended September 30, 2026, Genky DrugStores Co., Ltd. recorded 3.22B in income tax expense. That works out to an effective tax rate of 29.43, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.94B, leaving 7.72B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax3.22B
Effective Tax Rate29.43

Stock Price Statistics

JPY

As of the close on November 17, 2026, Genky DrugStores Co., Ltd.'s stock has declined approximately 26.01% over the past 52 weeks. The 50-day moving average sits at 3,525.80, while the 200-day moving average is 3,757.18.

52-Week Price Change-26.01%
50-Day Moving Average3,525.80
200-Day Moving Average3,757.18

Income Statement

JPY

Over the twelve months ended September 30, 2026, Genky DrugStores Co., Ltd. generated 224.10B in revenue and converted that into 7.72B in net income, yielding earnings per share of 252.40. EBITDA reached 10.83B, while operating income came in at 10.83B.

Revenue224.10B
Gross Profit45.68B
Operating Income10.83B
Pretax Income10.94B
Net Income7.72B
EBITDA10.83B
EBIT10.83B
Earnings Per Share (EPS)252.40

Balance Sheet

JPY

As of September 30, 2026, Genky DrugStores Co., Ltd. holds 13.93B in cash and equivalents against 40.47B in total debt, resulting in a net debt position of 26.55B. Total book value stands at 63.06B, with working capital of -2.70B providing operational flexibility.

Cash & Cash Equivalents13.93B
Total Debt40.47B
Net Debt26.55B
Equity (Book Value)63.06B
Book Value Per Share2,066.69
Working Capital-2.70B

Margins

Over the twelve months ended September 30, 2026, Genky DrugStores Co., Ltd. posted a gross margin of 20.38, reflecting its pricing power and cost economics. The operating margin of 4.83 and net profit margin of 3.44 provide insight into operational efficiency.

Gross Margin20.38
Operating Margin4.83
Pretax Margin4.88
Profit Margin3.44
EBITDA Margin4.83

Stock Splits

Genky DrugStores Co., Ltd.'s most recent stock split took place on June 19, 2024 with a 1:2 split ratio.

Last Split Date6/19/2024
Split Ratio1:2

Scores

As of September 30, 2026, Genky DrugStores Co., Ltd. has an Altman Z-Score of 2.90, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.90